Association between H19 polymorphisms and osteosarcoma risk
T.-D. He, D. Xu, T. Sui, J.-K. Zhu, Z.-X. Wei, Y.-M. Wang Department of Orthopedics, The First People’s Hospital of Changzhou, Changzhou, Jiangsu Province, China. doctorwym51346@163.com
OBJECTIVE: The long non-coding RNA (lncRNA) H19, a maternally expressed imprinted gene, has involvement in cancer susceptibility and disease progression. However, the association between H19 polymorphisms and osteosarcoma susceptibility has remained elusive. We designed this case-control study to explore the association between H19 polymorphism and osteosarcoma risk.
PATIENTS AND METHODS: In this study, we genotyped 4 tagger SNPs of the H19 gene in a case-control study including 193 osteosarcoma cases and 393 cancer-free controls.
RESULTS: For the main effect analysis, rs217727 (G>A) was associated with osteosarcoma risk (GA/GG: adjusted OR = 1.51, 95% CI: 1.06-2.17, p = 0.024; AA/GG: adjusted OR = 1.89, 95% CI: 1.23-2.91, p = 0.004; additive model: adjusted OR = 1.35, 95% CI: 1.01-1.80, p = 0.043).
CONCLUSIONS: This finding indicates that rs217727 polymorphism may play a role in genetic susceptibility to the risk of osteosarcoma, which may improve our understanding of the potential contribution of H19 SNPs to cancer pathogenesis.
Free PDF Download![Creative Commons License](https://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
T.-D. He, D. Xu, T. Sui, J.-K. Zhu, Z.-X. Wei, Y.-M. Wang
Association between H19 polymorphisms and osteosarcoma risk
Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 17
Pages: 3775-3780